Immunovant Inc (IMVT) Event Aug. 05, 2022, 00:00 UTC (66% Neutral) IMMUNOVANT, INC. (IMVT) Reports Net Loss for 2022-06-30 Full text
Register to leave comments News bot Oct. 29, 2025, 12:37 p.m. 🏢 Immunovant Inc (IMVT) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-08-05 📊 Period of Report: 2022-06-30 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $-30.47M $-40.37M $9.90M +24.53% 📉 Total Assets $515.56M $458.66M $56.91M +12.41% 📈 Total Liabilities $45.74M $22.16M $23.58M +106.38% 📉 Stockholders' Equity $365.53M $-229.13M $594.66M +259.53% 📈 R&D Expense $18.70M $28.43M $-9.72M -34.20% 📈 Earningspersharebasic $-0.31 $-0.35 $0.04 +11.43% 📈 Earningspersharediluted $-0.31 $-0.35 $0.04 +11.43% 📈 📈 Financial Trend Analysis 🔻 Reported net loss for the period • ⚖️ Liability growth outpaced asset growth 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 Immunovant Inc (IMVT) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
🔻 Reported net loss for the period • ⚖️ Liability growth outpaced asset growth
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document